BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BC Week In Review | Feb 8, 2010
Company News

Onyx management update

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), Emeryville, Calif.   Business: Cancer   Hired: Ted Love as EVP and head of R&D, formerly chairman, president and CEO of Nuvelo Inc.   Transitioned: Michael Kauffman to CMO from interim...
BC Extra | Feb 2, 2010
Company News

Onyx names Love head of R&D

Cancer company Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) hired Ted Love as EVP and head of R&D. Love was previously chairman, president and CEO of Nuvelo Inc. (NASDAQ:NUVO). Onyx also named Michael Kauffman CMO. Kauffman has served...
BC Week In Review | Jun 1, 2009
Company News

Arca biopharma cardiovascular news

Arca restructured and reduced headcount by about 40 (56%) to 31 as the biotech seeks strategic alternatives to commercialize its Gencaro bucindolol, including a co-marketing deal, a marketing partner or sale of the compound. The...
BC Week In Review | Feb 2, 2009
Company News

Arca biopharma, Nuvelo deal

Nuvelo and Arca completed their previously announced reverse merger (see BioCentury, Sept. 29, 2008). Arca biopharma Inc. , Broomfield, Colo.   Nuvelo Inc. (NASDAQ:NUVO), San Carlos, Calif.   Business: Cardiovascular  ...
BC Week In Review | Dec 22, 2008
Clinical News

NU206: Phase I data

Data from a double-blind, placebo-controlled, Australian Phase I trial in 32 healthy volunteers showed that a single dose of IV NU206 up to 0.2 mg/kg had a favorable safety profile with no serious adverse events....
BC Week In Review | Sep 29, 2008
Company News

Arca biopharma, Nuvelo deal

Nuvelo and cardiovascular company Arca agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will own 33%. The combined company will retain Arca's name and headquarters and will...
BioCentury | Sep 29, 2008
Product Development

BEST foot forward

FDA last week accepted for filing an NDA for Arca biopharma Inc. 's beta blocker, Gencaro bucindolol. But the company has an interesting circle to square. It is hoping the agency approves bucindolol to treat...
BioCentury | Sep 29, 2008
Finance

Ebb & Flow

Sequenom (NASDAQ:SQNM) has more than quadrupled its market cap to $1.6 billion from $350 million since early June, when the company released initial data on its Down syndrome test. The $1.2 billion uptick equates to...
BC Extra | Sep 26, 2008
Top Story

Nuvelo and Arca to reverse merge

Nuvelo (NASDAQ:NUVO) and cardiovascular company Arca (Broomfield, Colo.) agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will own 33%. The combined company will retain Arca's name and...
Items per page:
1 - 10 of 222
BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BC Week In Review | Feb 8, 2010
Company News

Onyx management update

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), Emeryville, Calif.   Business: Cancer   Hired: Ted Love as EVP and head of R&D, formerly chairman, president and CEO of Nuvelo Inc.   Transitioned: Michael Kauffman to CMO from interim...
BC Extra | Feb 2, 2010
Company News

Onyx names Love head of R&D

Cancer company Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) hired Ted Love as EVP and head of R&D. Love was previously chairman, president and CEO of Nuvelo Inc. (NASDAQ:NUVO). Onyx also named Michael Kauffman CMO. Kauffman has served...
BC Week In Review | Jun 1, 2009
Company News

Arca biopharma cardiovascular news

Arca restructured and reduced headcount by about 40 (56%) to 31 as the biotech seeks strategic alternatives to commercialize its Gencaro bucindolol, including a co-marketing deal, a marketing partner or sale of the compound. The...
BC Week In Review | Feb 2, 2009
Company News

Arca biopharma, Nuvelo deal

Nuvelo and Arca completed their previously announced reverse merger (see BioCentury, Sept. 29, 2008). Arca biopharma Inc. , Broomfield, Colo.   Nuvelo Inc. (NASDAQ:NUVO), San Carlos, Calif.   Business: Cardiovascular  ...
BC Week In Review | Dec 22, 2008
Clinical News

NU206: Phase I data

Data from a double-blind, placebo-controlled, Australian Phase I trial in 32 healthy volunteers showed that a single dose of IV NU206 up to 0.2 mg/kg had a favorable safety profile with no serious adverse events....
BC Week In Review | Sep 29, 2008
Company News

Arca biopharma, Nuvelo deal

Nuvelo and cardiovascular company Arca agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will own 33%. The combined company will retain Arca's name and headquarters and will...
BioCentury | Sep 29, 2008
Product Development

BEST foot forward

FDA last week accepted for filing an NDA for Arca biopharma Inc. 's beta blocker, Gencaro bucindolol. But the company has an interesting circle to square. It is hoping the agency approves bucindolol to treat...
BioCentury | Sep 29, 2008
Finance

Ebb & Flow

Sequenom (NASDAQ:SQNM) has more than quadrupled its market cap to $1.6 billion from $350 million since early June, when the company released initial data on its Down syndrome test. The $1.2 billion uptick equates to...
BC Extra | Sep 26, 2008
Top Story

Nuvelo and Arca to reverse merge

Nuvelo (NASDAQ:NUVO) and cardiovascular company Arca (Broomfield, Colo.) agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will own 33%. The combined company will retain Arca's name and...
Items per page:
1 - 10 of 222